Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Expected to Earn Q3 2023 Earnings of ($0.65) Per Share

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX – Get Rating) – Equities researchers at HC Wainwright issued their Q3 2023 earnings per share (EPS) estimates for Black Diamond Therapeutics in a research note issued to investors on Tuesday, March 14th. HC Wainwright analyst R. Burns anticipates that the company will post earnings of ($0.65) per share for the quarter. The consensus estimate for Black Diamond Therapeutics’ current full-year earnings is ($1.76) per share. HC Wainwright also issued estimates for Black Diamond Therapeutics’ Q4 2023 earnings at ($0.67) EPS and FY2023 earnings at ($2.56) EPS.

Black Diamond Therapeutics Price Performance

NASDAQ:BDTX opened at $1.67 on Thursday. The firm has a market capitalization of $60.92 million, a price-to-earnings ratio of -0.66 and a beta of 1.86. The business has a 50 day simple moving average of $2.44 and a 200-day simple moving average of $2.16. Black Diamond Therapeutics has a 1 year low of $1.18 and a 1 year high of $4.08.

Institutional Trading of Black Diamond Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Millennium Management LLC boosted its stake in shares of Black Diamond Therapeutics by 51.2% during the 4th quarter. Millennium Management LLC now owns 524,557 shares of the company’s stock worth $944,000 after purchasing an additional 177,577 shares during the period. EcoR1 Capital LLC bought a new stake in Black Diamond Therapeutics in the fourth quarter worth about $508,000. Marquette Asset Management LLC purchased a new position in shares of Black Diamond Therapeutics during the fourth quarter valued at approximately $62,000. Vanguard Group Inc. grew its stake in shares of Black Diamond Therapeutics by 13.9% during the third quarter. Vanguard Group Inc. now owns 757,098 shares of the company’s stock valued at $1,280,000 after buying an additional 92,141 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of Black Diamond Therapeutics by 572.2% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 82,881 shares of the company’s stock worth $140,000 after buying an additional 70,551 shares during the period. Hedge funds and other institutional investors own 59.10% of the company’s stock.

Black Diamond Therapeutics Company Profile

(Get Rating)

Black Diamond Therapeutics, Inc, a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations.